Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New prostate surgery technique aims to save erections and bladder control

NCT ID NCT03317990

Symptom relief Sponsor: University College, London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This trial tests a new surgical method called NeuroSAFE, which uses real-time tissue analysis during robotic prostate removal to help surgeons avoid damaging nerves that control erections and bladder function. About 407 men with prostate cancer will be randomly assigned to receive either the standard surgery or the NeuroSAFE technique. The main goal is to see if the new approach leads to better erectile function one year after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NeuroSAFE procedure (a surgical technique involving real-time analysis of removed tissue to guide nerve-sparing decisions)
What this could lead to
If successful, this technique could help men undergoing prostate cancer surgery retain better erectile function and urinary control, improving their quality of life.
What could go wrong
This is a relatively early-stage trial (IDEAL stage 3) with 407 participants, so results may not apply to all men. The technique requires specialized training and may not be widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

407 people

The number who actually took part.

Started

Apr 2018

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Men opting to undergo RARP for organ confined prostate cancer. 2. Potent men (IIEF 22-25 not using PDE5i or other medications or vacuum pump) 3. Men who are continent of urine (no self-reported urinary incontinence) 4. Has given written informed consent 5. Ability to read English sufficiently to answer questionnaires and understand PIS Exclusion Criteria: 1. Unable to undergo robotic prostatectomy 2. Known urinary incontinence 3. Previous treatment for prostate cancer 4. Previous/current hormone treatment for prostate cancer 5. Nerve sparing deemed futile due to locally advanced disease by surgeon and radiologist

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • NHS Greater Glasgow & Clyde

    Glasgow, United Kingdom

  • North Bristol NHS Trust

    Bristol, BS10 5NB, United Kingdom

  • Nottingham University Hospitals

    Nottingham, United Kingdom

  • Sheffield Teaching Hospitals NHS Foundation Trust

    Sheffield, S10 2JF, United Kingdom

  • University College London Hospital

    London, NW1 2BU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.